STOCK TITAN

CNTA Form 144: Insider Exercise and Planned UBS Sale of 20,000 Shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice for proposed sale of securities. The filing shows a proposed sale of 20,000 shares of common stock through UBS Financial Services on 09/09/2025 on Nasdaq with an aggregate market value of $400,102.00. The shares were acquired the same day by exercise of stock options from the issuer and paid in cash. The filer also reported three prior sales during the past three months totaling 24,000 common shares with gross proceeds of $360,165.20 from sales on 06/24/2025, 07/15/2025, and 08/15/2025. The filing includes the seller's name and broker details.

Positive

  • Transparent disclosure of a proposed Rule 144 sale with broker, quantity, dates, and aggregate market value
  • Prior dispositions during the past three months are itemized with dates and gross proceeds
  • Acquisition method disclosed as exercise of stock options and paid in cash

Negative

  • None.

Insights

TL;DR: Routine Rule 144 notice disclosing an insider exercise and planned sale; prior small-volume dispositions are reported.

The filing documents a proposed resale under Rule 144 of 20,000 common shares executed through UBS Financial Services and acquired on the same date by option exercise and paid in cash. It also discloses three prior dispositions totaling 24,000 shares across June–August 2025. From a compliance perspective, the notice provides required broker, quantity, and timing details and includes the signer’s representation about possession of material nonpublic information.

TL;DR: Insider-related share sales and option exercise are disclosed; amounts represent a small fraction of outstanding shares.

The filing reports a proposed market sale of 20,000 shares valued at $400,102 and prior sales aggregating 24,000 shares with gross proceeds of $360,165.20. With 134,073,436 shares outstanding indicated in the form, the disclosed transactions are small on a percentage basis. The document supplies clear trade dates, broker details, and the nature of acquisition

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for CNTA disclose about the proposed sale?

It discloses a proposed sale of 20,000 common shares through UBS on 09/09/2025 with an aggregate market value of $400,102.00.

How were the 20,000 shares acquired according to the filing?

The filing states the shares were acquired on 09/09/2025 by exercise of stock options from the issuer and paid in cash.

What prior insider sales are reported in the Form 144?

Three prior sales are listed: 06/24/2025 (12,000 shares), 07/15/2025 (6,000 shares), and 08/15/2025 (6,000 shares), totaling 24,000 shares with gross proceeds of $360,165.20.

Which broker is named for the proposed sale in the filing?

The broker listed is UBS Financial Services Inc., Eleven Madison Avenue, New York, NY.

How many shares outstanding does the Form 144 show?

The filing shows 134,073,436 shares outstanding.
Centessa Pharmaceuticals Plc

NASDAQ:CNTA

CNTA Rankings

CNTA Latest News

CNTA Latest SEC Filings

CNTA Stock Data

3.27B
133.70M
0.49%
93.69%
3.93%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
ALTRINCHAM, CHESHIRE